Zacks Investment Research lowered shares of Bellerophon Therapeutics (NASDAQ:BLPH) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other research analysts have also recently issued reports on BLPH. Maxim Group assumed coverage on Bellerophon Therapeutics in a research note on Thursday, January 24th. They set a buy rating and a $3.00 price objective on the stock. HC Wainwright reaffirmed a buy rating and set a $3.00 price objective on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th. Finally, ValuEngine cut Bellerophon Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 20th.

NASDAQ BLPH opened at $0.65 on Thursday. Bellerophon Therapeutics has a twelve month low of $0.47 and a twelve month high of $3.30. The stock has a market cap of $44.86 million, a price-to-earnings ratio of -1.91 and a beta of -0.01.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.10. As a group, equities research analysts forecast that Bellerophon Therapeutics will post -0.52 EPS for the current fiscal year.

In related news, Director Naseem Amin acquired 571,429 shares of Bellerophon Therapeutics stock in a transaction dated Friday, January 25th. The shares were purchased at an average cost of $0.70 per share, with a total value of $400,000.30. Following the completion of the purchase, the director now owns 1,818,867 shares of the company’s stock, valued at $1,273,206.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. 53.10% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC grew its stake in shares of Bellerophon Therapeutics by 60.2% during the fourth quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 13,799 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Bellerophon Therapeutics by 2.5% in the third quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock worth $1,105,000 after purchasing an additional 25,300 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Bellerophon Therapeutics by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 27,027 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Bellerophon Therapeutics by 4.7% in the third quarter. Renaissance Technologies LLC now owns 1,213,276 shares of the biotechnology company’s stock worth $1,310,000 after purchasing an additional 54,076 shares during the last quarter. 47.63% of the stock is currently owned by hedge funds and other institutional investors.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Further Reading: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.